牛牛AI助理已提取核心訊息
Cybin Inc., a biopharmaceutical company listed as CYBN on the NYSE American LLC, filed an amended report with the U.S. Securities and Exchange Commission (SEC) on February 15, 2024. The amendment, Form 6-K/A, was submitted to incorporate Exhibits 99.1 and 99.2 into the company's Registration Statement on Form F-10. This amendment does not change the original report filed on February 14, 2024, except for the specified exhibits. Cybin's interim consolidated financial statements for the nine months ended December 31, 2023, show a significant increase in total assets, from CAD 53.9 million to CAD 129.7 million, and an increase in shareholders' equity from CAD 48.2 million to CAD 121.2 million. The company reported a net loss of CAD 56.7 million for the nine-month period, compared to CAD 33.8 million in...Show More
Cybin Inc., a biopharmaceutical company listed as CYBN on the NYSE American LLC, filed an amended report with the U.S. Securities and Exchange Commission (SEC) on February 15, 2024. The amendment, Form 6-K/A, was submitted to incorporate Exhibits 99.1 and 99.2 into the company's Registration Statement on Form F-10. This amendment does not change the original report filed on February 14, 2024, except for the specified exhibits. Cybin's interim consolidated financial statements for the nine months ended December 31, 2023, show a significant increase in total assets, from CAD 53.9 million to CAD 129.7 million, and an increase in shareholders' equity from CAD 48.2 million to CAD 121.2 million. The company reported a net loss of CAD 56.7 million for the nine-month period, compared to CAD 33.8 million in the previous year. The financial statements also highlight the acquisition of Small Pharma Inc., which became a wholly-owned subsidiary of Cybin on October 23, 2023. The acquisition resulted in an increase in goodwill and intangible assets on Cybin's balance sheet. Cybin's CEO, Doug Drysdale, signed the report, indicating the company's commitment to advancing psychedelic-based therapies for psychiatric and neurological conditions.
在紐約證券交易所美國有限責任公司以CYBN的名義上市的生物製藥公司Cybin Inc. 於2024年2月15日向美國證券交易委員會（SEC）提交了經修訂的報告。提交了6K/A表格的修正案，目的是將附錄99.1和99.2納入公司在F-10表格上的註冊聲明中。除特定證物外，該修正案並未更改2024年2月14日提交的原始報告。Cybin截至2023年12月31日的九個月中期合併財務報表顯示，總資產大幅增加，從5,390萬加元增至1.297億加元，股東權益從4,820萬加元增加至1.212億加元。該公司報告稱，九個月期間的淨虧損爲5,670萬加元，而去年同期爲3,380萬加元。財務報表還重點介紹了對小型製藥公司的收購，該公司於2023年10月23日成爲Cybin的全資子公司。此次收購導致Cybin資產負債表上的商譽和無形資產增加。Cybin的首席執行官道格·德賴斯代爾簽署了該報告，表明該公司致力於推進基於迷幻藥的精神和神經系統疾病療法。
在紐約證券交易所美國有限責任公司以CYBN的名義上市的生物製藥公司Cybin Inc. 於2024年2月15日向美國證券交易委員會（SEC）提交了經修訂的報告。提交了6K/A表格的修正案，目的是將附錄99.1和99.2納入公司在F-10表格上的註冊聲明中。除特定證物外，該修正案並未更改2024年2月14日提交的原始報告。Cybin截至2023年12月31日的九個月中期合併財務報表顯示，總資產大幅增加，從5,390萬加元增至1.297億加元，股東權益從4,820萬加元增加至1.212億加元。該公司報告稱，九個月期間的淨虧損爲5,670萬加元，而去年同期爲3,380萬加元。財務報表還重點介紹了對小型製藥公司的收購，該公司於2023年10月23日成爲Cybin的全資子公司。此次收購導致Cybin資產負債表上的商譽和無形資產增加。Cybin的首席執行官道格·德賴斯代爾簽署了該報告，表明該公司致力於推進基於迷幻藥的精神和神經系統疾病療法。
有用
沒用